

Giuseppe Lopalco

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9347951/giuseppe-lopalco-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

158
papers

2,456
citations

28
h-index

40
g-index

189
ext. papers

3,189
ext. citations

3.7
avg, IF

5.07
L-index

#	Paper	IF	Citations
158	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis.. <i>Ophthalmology and Therapy</i> , 2022 , 11, 899	5	2
157	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis.. <i>Ophthalmology and Therapy</i> , 2022 , 11, 887	5	1
156	Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors.. <i>RMD Open</i> , 2022 , 8,	5.9	2
155	Development and Implementation of the AIDA International Registry for Patients With Still's Disease.. <i>Frontiers in Medicine</i> , 2022 , 9, 878797	4.9	0
154	Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering.. <i>Frontiers in Immunology</i> , 2022 , 13, 860877	8.4	1
153	Complete Hydatidiform Mole Mimicking Sacroiliitis. <i>Journal of Clinical Rheumatology</i> , 2021 , 27, e122	1.1	2
152	Anakinra effectiveness in refractory polyserositis: An Italian multicenter study. <i>Joint Bone Spine</i> , 2021 , 89, 105299	2.9	2
151	Interleukin 1 α comprehensive review on the role of IL-1 α in the pathogenesis and treatment of autoimmune and inflammatory diseases. <i>Autoimmunity Reviews</i> , 2021 , 20, 102763	13.6	44
150	Clinical profile and evolution of patients with juvenile-onset Behçet's syndrome over a 25-year period: insights from the AIDA network. <i>Internal and Emergency Medicine</i> , 2021 , 16, 2163-2171	3.7	1
149	High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry. <i>Clinical Rheumatology</i> , 2021 , 40, 3659-3665	3.9	0
148	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). <i>European Respiratory Journal</i> , 2021 , 57,	13.6	7
147	OP0093 RETENTION RATE OF IL-1 INHIBITORS IN PATIENTS WITH SCHNITZLER'S SYNDROME. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 51-52	2.4	1
146	AB0380 MACHINE LEARNING CAN PREDICT GIANT CELL ARTERITIS RELAPSE AFTER GLUCOCORTICOID TAPERING. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1217-1217	2.4	
145	Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry. <i>Rheumatology</i> , 2021 , 60, 5705-5712	3.9	1
144	POS0631 COMPARATIVE EFFICACY OF COMBINATION THERAPY WITH BIOLOGIC OR TARGET SYNTHETIC DRUGS FOR RHEUMATOID ARTHRITIS: A BAYESIAN NETWORK META-ANALYSIS. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 553.2-554	2.4	
143	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. <i>Frontiers in Medicine</i> , 2021 , 8, 668173	4.9	3
142	Predictors of long-term clinical remission in rheumatoid arthritis. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13363	4.6	2

141	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. <i>Joint Bone Spine</i> , 2021 , 88, 105062	2.9	5
140	Histopathologic Features of Fibrotic Knee Synovitis in a Young Adult With Seronegative Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2021 , 27, e73-e74	1.1	2
139	A convolutional neural network with transfer learning for automatic discrimination between low and high-grade synovitis: a pilot study. <i>Internal and Emergency Medicine</i> , 2021 , 16, 1457-1465	3.7	9
138	Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X211037178	3.8	0
137	A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic Agents. <i>Journal of Clinical Rheumatology</i> , 2021 ,	1.1	7
136	The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment. <i>Trends in Cardiovascular Medicine</i> , 2021 , 31, 265-274	6.9	9
135	Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study. <i>Arthritis and Rheumatology</i> , 2021 , 74, 295	9.5	5
134	Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection. <i>Internal and Emergency Medicine</i> , 2021 , 1	3.7	0
133	Histopathological characteristics of synovitis in Familial Mediterranean Fever (FMF). <i>Joint Bone Spine</i> , 2021 , 89, 105259	2.9	
132	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 187-195	2.2	6
131	Successful treatment with anakinra of refractory pericarditis in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 227	2.2	1
130	Safety and effectiveness in switching from reference to biosimilar rituximab in rheumatoid arthritis patients: real world experience from a single Italian rheumatology centre. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 1147-1148	2.2	
129	Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into Behçet's Syndrome.. <i>Frontiers in Medicine</i> , 2021 , 8, 769870	4.9	0
128	Successful treatment with anakinra of refractory pericarditis in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 227-227	2.2	5
127	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 187-195	2.2	11
126	Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 42, 102152	4	3
125	Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: a multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1098-1104	2.4	16
124	Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast. <i>Clinical and Experimental Immunology</i> , 2020 , 201, 200-204	6.2	4

123	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , 2020 , 7, 42	4.9	6
122	Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. <i>Inflammopharmacology</i> , 2020 , 28, 711-718	5.1	7
121	COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence. <i>Rheumatology International</i> , 2020 , 40, 827-828	3.6	24
120	Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics. <i>Internal and Emergency Medicine</i> , 2020 , 15, 1031-1039	3.7	6
119	OP0148 MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A RETROSPECTIVE REAL-WORLD EUROPEAN STUDY ON 142 PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 94-95	2.4	1
118	New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy. <i>Mediators of Inflammation</i> , 2020 , 2020, 8294560	4.3	10
117	AB0844 SERUM sCD40L LEVEL CAN PREDICT SHORT-TERM CLINICAL OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS ON TREATMENT WITH APREMILAST.. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1728-1729	2.4	
116	Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis. <i>Rheumatology</i> , 2020 , 59, 1599-1606	3.9	15
115	Splenic Infarction as Only Manifestation of Antiphospholipid Syndrome in a Patient With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2020 , 26, e102	1.1	
114	Paradoxical Pustular Psoriasis in a Patient With Psoriatic Arthritis on Secukinumab Treatment. <i>Journal of Clinical Rheumatology</i> , 2020 , 26, e208-e209	1.1	2
113	Discordance between patient and physician global assessment of disease activity in Behçet's syndrome: a multicenter study cohort. <i>Arthritis Research and Therapy</i> , 2020 , 22, 278	5.7	1
112	Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI). <i>RMD Open</i> , 2020 , 6,	5.9	7
111	Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease. <i>Mediators of Inflammation</i> , 2020 , 2020, 8054961	4.3	8
110	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. <i>Mediators of Inflammation</i> , 2020 , 2020, 8562485	4.3	13
109	Safety of systemic treatments for Behçet's syndrome. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 1269-1301	4.1	3
108	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. <i>Archives of Rheumatology</i> , 2020 , 35, 163-169	0.9	0
107	Influence of changes in cholesterol levels and disease activity on the 10 years cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e104	2.4	3
106	The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease. <i>Ocular Immunology and Inflammation</i> , 2020 , 28, 298-304	2.8	26

105	Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 956-964 ^{3.9}	3.9	53
104	Response to: 'Response to: "Influence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients" by Fornaro ' by Agca. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e106	2.4	
103	Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis. <i>Mediators of Inflammation</i> , 2020 , 2020, 6983272	4.3	8
102	Efficacy of monoclonal anti-tumour necrosis factor- α antibodies in uveitic macular oedema. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 621-625	2.2	
101	Reply to Praprotnik and Tomsic and erratum corrigé. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 1034	2.2	
100	Effectiveness of TNF- α blockade in the treatment of refractory non-infectious scleritis: a multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 1138-1144	2.2	3
99	A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2019 , 38, 1309-1317	3.9	9
98	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. <i>Frontiers in Pharmacology</i> , 2019 , 10, 918	5.6	13
97	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019 , 10, 296	5.6	17
96	Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	41
95	The right place of interleukin-1 inhibitors in the treatment of Behçet's syndrome: a systematic review. <i>Rheumatology International</i> , 2019 , 39, 971-990	3.6	23
94	Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. <i>Clinical Rheumatology</i> , 2019 , 38, 407-415	3.9	34
93	Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study. <i>Mediators of Inflammation</i> , 2019 , 2019, 1623847	4.3	16
92	The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF- α Inhibitors. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1468	5.6	7
91	Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1736-1737	2.4	15
90	Tomographic regression of pulmonary rheumatoid nodules under baricitinib therapy. <i>Rheumatology</i> , 2019 , 58, 440	3.9	2
89	Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet's disease. <i>Internal and Emergency Medicine</i> , 2019 , 14, 719-722	3.7	9
88	Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis. <i>Ocular Immunology and Inflammation</i> , 2019 , 27, 34-39	2.8	25

87	Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. <i>Clinical Rheumatology</i> , 2019 , 38, 63-70	3.9	22
86	Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus. <i>Rheumatology</i> , 2019 ,	3.9	3
85	Efficacy of anti-tumour necrosis factor- α monoclonal antibodies in patients with non-infectious anterior uveitis. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 301-305	2.2	7
84	Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 680-683	2.2	19
83	Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 762-767	2.2	9
82	Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1526	5.6	6
81	Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab. <i>Clinical Rheumatology</i> , 2018 , 37, 1715-1720	3.9	12
80	Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. <i>Internal and Emergency Medicine</i> , 2018 , 13, 475-489	3.7	42
79	Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review. <i>Rheumatology International</i> , 2018 , 38, 25-35	3.6	8
78	Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study. <i>British Journal of Ophthalmology</i> , 2018 , 102, 637-641	5.5	30
77	Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings. <i>European Journal of Clinical Investigation</i> , 2018 , 48, e13013	4.6	28
76	Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases. <i>Current Cardiology Reports</i> , 2018 , 20, 61	4.2	21
75	Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment. <i>Mediators of Inflammation</i> , 2018 , 2018, 2453265	4.3	21
74	Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	37
73	Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behcet's disease. <i>Immunology Letters</i> , 2018 , 201, 38-44	4.1	17
72	Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. <i>Clinical Rheumatology</i> , 2018 , 37, 2805-2809	3.9	28
71	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2018 , 37, 2233-2240	3.9	52
70	Correlation of Serum Amyloid-A Levels, Clinical Manifestations, Treatment, and Disease Activity in Patients with Behçet's Disease. <i>Israel Medical Association Journal</i> , 2018 , 20, 517-521	0.9	3

69	Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers. <i>Israel Medical Association Journal</i> , 2018 , 20, 438-441	0.9	6
68	Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 68-73	2.2	14
67	A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome. <i>Clinical Rheumatology</i> , 2017 , 36, 463-468	3.9	48
66	Canakinumab efficacy in refractory adult-onset PFAPA syndrome. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 1050-1051	2.3	21
65	Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 103-108	2.3	19
64	Certolizumab Pegol treatment in Behçet's disease with different organ involvement: A multicenter retrospective observational study. <i>Modern Rheumatology</i> , 2017 , 27, 1031-1035	3.3	27
63	Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease. <i>Clinical Rheumatology</i> , 2017 , 36, 2063-2069	3.9	23
62	IL-6 blockade in the management of non-infectious uveitis. <i>Clinical Rheumatology</i> , 2017 , 36, 1459-1469	3.9	24
61	Rapid desensitization to anakinra-related delayed reaction: Need for a standardized protocol. <i>Journal of Dermatology</i> , 2017 , 44, 981-982	1.6	7
60	Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2017 , 36, 191-197	3.9	74
59	Pain Processing and Vegetative Dysfunction in Fibromyalgia: A Study by Sympathetic Skin Response and Laser Evoked Potentials. <i>Pain Research and Treatment</i> , 2017 , 2017, 9747148	1.9	14
58	Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Behçet disease uveitis and concomitant bladder papillary carcinoma. <i>Internal Medicine Journal</i> , 2017 , 47, 1086-1088	1.6	10
57	Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2017 , 36, 183-189	3.9	59
56	Auditory involvement in Behçet's disease: relationship with demographic, clinical, and therapeutic characteristics. <i>Clinical Rheumatology</i> , 2017 , 36, 445-449	3.9	3
55	Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2017 , 36, 451-455	3.9	45
54	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2017 , 8, 369	5.6	68
53	Update on the Medical Management of Gastrointestinal Behçet's Disease. <i>Mediators of Inflammation</i> , 2017 , 2017, 1460491	4.3	14
52	Cytokine Signatures in Mucocutaneous and Ocular Behçet's Disease. <i>Frontiers in Immunology</i> , 2017 , 8, 200	8.4	42

51	Long-term tocilizumab efficacy in a patient with psoriatic arthritis and AA amyloidosis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 170-171	2.2	2
50	Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 93-97	2.2	7
49	Intravitreal Dexamethasone Implant as an Adjunct Weapon for Severe and Refractory Uveitis in Behçet's Disease. <i>Israel Medical Association Journal</i> , 2017 , 19, 415-419	0.9	6
48	Ustekinumab efficacy and safety in mucocutaneous multi-refractory Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 108, 130-131	2.2	5
47	Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study. <i>Clinical Rheumatology</i> , 2016 , 35, 1281-6	3.9	72
46	SAT0384 Long-Term Safety of Anti-Tnf Agents in Patients with Spondyloarthritis and Potential Occult HBV: An Observational Multicenter Study on 131 Patients. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 807.1-807	2.4	
45	SAT0216 Chest Ultrasound Signs of Interstitial Lung Disease in Systemic Sclerosis Patients: A Comparison between High Resolution Chest Computed Tomography Findings. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 747.1-747	2.4	1
44	PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. <i>Clinical Rheumatology</i> , 2016 , 35, 501-5	3.9	24
43	Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. <i>Autoimmunity Reviews</i> , 2016 , 15, 447-50	13.6	44
42	Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings. <i>Journal of Rheumatology</i> , 2016 , 43, 911-7	4.1	13
41	Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016 , 35, 19-23	3.9	8
40	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2016 , 7, 380	5.6	57
39	Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists' lens. <i>Internal and Emergency Medicine</i> , 2016 , 11, 781-91	3.7	10
38	Heterogeneous clinical spectrum of interstitial lung disease in patients with anti-EJ anti-synthetase syndrome: a case series. <i>Clinical Rheumatology</i> , 2016 , 35, 2363-7	3.9	15
37	Management of Small Vessel Vasculitides. <i>Current Rheumatology Reports</i> , 2016 , 18, 36	4.9	7
36	New therapeutic solutions for Behçet's syndrome. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 827-409		31
35	Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. <i>Clinical Rheumatology</i> , 2016 , 35, 2631-2638	3.9	19
34	Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 424-9	2.2	11

33	Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 531-8	2.2	22
32	Anakinra long-term efficacy and safety in the management of Schnitzler's syndrome and latent tuberculosis infection. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 353	2.2	7
31	Interleukin-1 Inhibition in Behçet's disease. <i>Israel Medical Association Journal</i> , 2016 , 18, 171-6	0.9	22
30	Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet's Disease with Different Organ Involvement: A Case Series. <i>Israel Medical Association Journal</i> , 2016 , 18, 238-42	0.9	17
29	Demographic, clinical and therapeutic findings in a monocentric cohort of adult patients with suspected PFAPA syndrome. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 77-81	2.2	19
28	The protean ocular involvement in monogenic autoinflammatory diseases: state of the art. <i>Clinical Rheumatology</i> , 2015 , 34, 1171-80	3.9	12
27	Non-canonical manifestations of familial Mediterranean fever: a changing paradigm. <i>Clinical Rheumatology</i> , 2015 , 34, 1503-11	3.9	13
26	Role of nerve growth factor and tropomyosin receptor kinase A in the pathogenesis of osteoarthritis. Might nerve growth factor be the link intertwining obesity and osteoarthritis?. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e70	2.4	2
25	Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. <i>Autoimmunity Reviews</i> , 2015 , 14, 90-7	13.6	42
24	The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy. <i>Clinical Rheumatology</i> , 2015 , 34, 17-28	3.9	36
23	Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. <i>Autoimmunity Reviews</i> , 2015 , 14, 1-9	13.6	70
22	Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. <i>Clinical Rheumatology</i> , 2015 , 34, 807-9	3.9	17
21	Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab. <i>Clinical Rheumatology</i> , 2015 , 34, 1141-3	3.9	40
20	Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease. <i>Medicine (United States)</i> , 2015 , 94, e1858	1.8	28
19	Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of Infliximab: a case series and review of the literature. <i>International Journal of Rheumatic Diseases</i> , 2015 , 18, 908-12	2.3	2
18	Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant. <i>International Journal of Rheumatic Diseases</i> , 2015 , 18, 473-5	2.3	5
17	AB0065 Possible Interplay Between Serum Amyloid-A and Pro-Inflammatory Cytokines Into the Pathogenesis of Behçet's Disease. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 912.2-912	2.4	
16	AB0452 Changes in Lipoproteins Associated with Tocilizumab Treatment Do not Influence the Atherogenic Index of Plasma of Rheumatoid Arthritis Patients. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1046.3-1047	2.4	

15	Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. <i>Hepatology</i> , 2015 , 62, 40-6	11.2	60
14	Coexistence of axial spondyloarthritis and thromboangiitis obliterans in a young woman. <i>Reumatismo</i> , 2015 , 67, 17-20	1.1	1
13	Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease. <i>Pediatric Rheumatology</i> , 2015 , 13,	3.5	3
12	Basic Characteristics of Adults with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy Syndrome in Comparison with the Typical Pediatric Expression of Disease. <i>Mediators of Inflammation</i> , 2015 , 2015, 570418	4.3	29
11	Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives. <i>Mediators of Inflammation</i> , 2015 , 2015, 451675	4.3	17
10	Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. <i>Mediators of Inflammation</i> , 2015 , 2015, 194864	4.3	64
9	Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa. <i>Medicine (United States)</i> , 2015 , 94, e1528	1.8	30
8	Adult-onset tumour necrosis factor receptor-associated periodic syndrome presenting with refractory chronic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S171-2	2.2	6
7	Interleukin-1: Ariadne's Thread in Autoinflammatory and Autoimmune Disorders. <i>Israel Medical Association Journal</i> , 2015 , 17, 93-7	0.9	17
6	Serum amyloid-A in Behçet's disease. <i>Clinical Rheumatology</i> , 2014 , 33, 1165-7	3.9	13
5	Different switching rate of anti-TNF- α drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life. <i>Joint Bone Spine</i> , 2014 , 81, 458-9	2.9	6
4	Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. <i>Clinical Rheumatology</i> , 2014 , 33, 1197-207	3.9	49
3	A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy. <i>Reumatismo</i> , 2014 , 65, 298-301	1.1	3
2	Untangling the web of systemic autoinflammatory diseases. <i>Mediators of Inflammation</i> , 2014 , 2014, 948154	1.54	22
1	Retinal vessels thrombosis as onset manifestation of systemic sclerosis: 3 clinical cases. <i>Journal of Rheumatology</i> , 2014 , 41, 2495-6	4.1	5